https://epidermolysisbullosanews.com/news/dystrophic-epidermolysis-bullosa-deb-krystal-files-new-drug-application-kb103-gene-therapy/
For DEB Gene Therapy Candidate KB103, Krystal Files New Drug Application
Mar 28, 2018 - Read about Krystal's FDA application to start a clinical trial testing KB103, its lead gene therapy candidate for dystrophic epidermolysis bullosa.
new drug applicationgene therapydebcandidatekrystal
https://healthchanneltogo.com/article/897177350-priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in...
new drug applicationand priorityannouncesfdaacceptance
https://www.industryfocusswitzerland.com/article/940528094-belite-bio-announces-submission-of-new-drug-application-to-the-ministry-of-health-labour-and-welfare-in-japan-under-the-sakigake-designation-system
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and...
Industry Focus Switzerland is an online news publication focusing on industries in the Switzerland: Reporting on industries and services news in Switzerland
new drug applicationto thebelitebioannounces
https://www.fdamap.com/services/nda-services.html
Navigating Your Path to Market: Expert New Drug Application (NDA) Services
Jan 12, 2026 - Navigating Your Path to Market: Expert New Drug Application (NDA) Services Bringing a novel pharmaceutical product from the laboratory to the pharmacy shelf is...
new drug applicationnavigatingpathmarketexpert
https://www.biospace.com/poseida-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-p-cd19cd20-allo1-an-allogeneic-dual-car-t-cell-therapy-for-b-cell-malignancies
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for...
Jul 5, 2023 - Poseida Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for...
investigational new drugtherapeuticsannouncesfdaclearance
https://www.datalilyai.com/glossary/new-drug-application-nda
New Drug Application (NDA): Definition & Meaning | DataLily AI
A New Drug Application (NDA) is the formal submission a sponsor files with the FDA seeking approval to market a new small-molecule drug.
new drug applicationndadefinitionmeaning
https://www.businesswire.com/news/home/20200203005253/en/FDA-Accepts-For-Review-Supplemental-New-Drug-Application-sNDA-for-RECARBRIO-imipenem-cilastatin-and-relebactam-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP
FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem,...
FDA Accepts For Review sNDA for RECARBRIO™ for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
new drug applicationfdaacceptsreviewsupplemental
https://www.healthupdatebahamas.com/article/897177350-priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in...
new drug applicationand priorityannouncesfdaacceptance
https://www.news-medical.net/whitepaper/20220307/Insights-into-the-Process-of-a-New-Drug-Application.aspx
Insights into the process of a new drug application
Jul 11, 2024 - This article discusses the strategy needed to process a new drug application or biological license application.
new drug applicationthe processinsights
https://www.northdakotatechnologyreview.com/article/845665891-achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment...
new drug applicationlife sciencesachieveannouncesfda
https://marijuanastocks.com/abbv-submits-supplemental-new-drug-application-to-u-s-fda/?amp
AbbVie Inc. (ABBV) Submits Supplemental New Drug Application to U.S. FDA - Marijuana Stocks |...
Jun 21, 2022 - AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine...
new drug applicationabbvie incsubmitssupplementalfda
https://www.basilea.com/news/news/basilea-announces-submission-of-investigational-new-drug-application-for-novel-oncology-drug-candidate-bal0891
Basilea announces submission of Investigational New Drug application for novel oncology drug...
investigational new drugbasileaannouncessubmissionapplication
https://www.healthdailysouthcarolina.com/article/888985285-prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-ind-for-prt12396-a-mutant-selective-jak2v617f-inhibitor
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for...
investigational new drugpreludetherapeuticsreceivesfda
https://www.curefa.org/news/design-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-first-genetac-molecule-for-friedreich-ataxia/
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First...
investigational new drugdesigntherapeuticsannouncesfda
https://corp.arcalis.co.jp/en/news/meiji-seika-pharma-submitted-new-drug-application-to-manufacture-and-market-arct-154-in-japan/
Meiji Seika Pharma Submitted New Drug Application to Manufacture and Market ARCT-154 in...
ARCALIS was founded in 2021 as a joint venture between Axcelead, Inc. and Arcturus Therapeutics. The company provides drug discovery support, CMC development,...
meiji seika pharmanew drug applicationsubmittedmanufacturemarket
https://www.rnexltd.ie/renexxion-ireland-ltd-announces-fda-clearance-of-investigational-new-drug-ind-application-for-naronapride-to-treat-ppi-non-responsive-symptomatic-gerd.html
Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for...
ROSCREA, Ireland, January 24, 2024 – Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to...
investigational new drugirelandltdannouncesfda
https://ascopost.com/issues/july-1-2012/supplemental-new-drug-application-submitted-for-abiraterone/
Supplemental New Drug Application Submitted for Abiraterone - The ASCO Post
new drug applicationthe asco postsupplementalsubmittedabiraterone
https://elevartx.com/2026/03/30/elevar-fda-acceptance-lira/
Elevar Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for...
Mar 31, 2026 - FDA set a Sept. 27 PDUFA date for approval decision Lirafugratinib achieved a 46.5% ORR, in CCA patients with FGFR2 fusion and rearrangement Fort Lee, N.J.,...
new drug applicationpriority reviewelevartherapeuticsannounces
https://www.center4research.org/nchr-testimony-fda-joint-meeting-pulmonary-allergy-drugs-advisory-committee-drug-safety-risk-management-advisory-committee-new-drug-application-asthma/
NCHR Testimony at FDA on a New Drug Application for Asthma - National Center for Health Research
Mar 16, 2017 - March 19, 2015. Long-acting beta-agonists have a history of serious adverse events in asthma patients including a four-fold increase in asthma-related death....
new drug applicationhealth researchtestimonyfdaasthma
https://globalrwc.com/case-studies/medical-writing-case-study
Investigational New Drug Application Medical Writing Case Study
GLOBAL made sure the client's investigational new drug application was submitted on time and followed all FDA requirements.
investigational new drugmedical writingcase studyapplication
https://www.massbio.org/news/recent-news/when-do-you-begin-planning-your-investigational-new-drug-application-ind/
When Do You Begin Planning Your Investigational New Drug Application (IND)? - MassBio
Mar 26, 2020 - In our guest blog, Kevin Hennegan, Senior Regulatory Strategist, Veristat discusses when companies should submit an IND application to the FDA and what to keep...
investigational new drugdo youbegin planningapplicationind
https://www.healthcap.eu/media/strongbridge-biopharma-plc-announces-submission-of-new-drug-application-for-recorlev-levoketoconazole-for-the-treatment-of-endogenous-cushings-syndrome-to-the-u-s-food-drug-adminis/
Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV®...
RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS...
new drug applicationbiopharmaplcannouncessubmission
https://www.pharmather.com/news-releases/pharmather-provides-update-of-its-priority-original-abbreviated-new-drug-application-for-ketamine6168232
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine |...
PharmaTher current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions...
new drug applicationprovidesupdatepriorityoriginal
https://www.healthdigestcookislands.com/article/871901641-biofrontera-inc-announces-filing-of-supplemental-new-drug-application-snda-for-the-treatment-of-superficial-basal-cell-carcinoma-sbcc-with
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of...
new drug applicationfor theincannouncesfiling
https://www.biospace.com/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment...
Jun 27, 2023 - Allecra Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic...
new drug applicationto thetherapeuticssubmitsfda
https://www.jnj.com/media-center/press-releases/new-drug-application-submitted-to-fda-for-tapentadol-extended-release-tablets-for-management-of-chronic-pain
New Drug Application Submitted To FDA for Tapentadol Extended Release Tablets for Management of...
new drug applicationextended releasesubmittedfdatapentadol
https://www.biopharmaapac.com/news/83/7187/lundbeck-moves-closer-to-asian-launch-of-vyepti-with-new-drug-application-accepted-in-japan.html
Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan
Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan
new drug applicationcloser toin japanlundbeckmoves
https://www.astrazeneca.com/media-centre/press-releases/2009/AstraZeneca-Submits-US-New-Drug-Application-for-Brilinta-19112009.html
AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor), an Investigational...
AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor), an Investigational Antiplatelet Agent
new drug applicationastrazenecasubmitsbrilintaticagrelor
https://www.appliedclinicaltrialsonline.com/view/fda-clears-investigational-new-drug-application-phase-ib-iia-trial-ck0802-steroid-refractory-graft-versus-host-disease
FDA Clears Investigational New Drug Application for Phase Ib/IIa Trial of CK0802 in...
Oct 5, 2026 - FDA clears Cellenkos’ IND for CK0802, enabling a mid-stage trial in steroid-refractory GVHD.
investigational new drugphase ibfdaclearsapplication
https://drugdevelopment.web.unc.edu/u-s-investigational-new-drug-application-%E2%86%92-types-of-inds/
U.S. Investigational New Drug Application → Types of INDs | Developing Medicines
investigational new drugapplicationtypesindsdeveloping
https://pharmapress.co.uk/brands/ddd/5388/
Kali Therapeutics Receives US FDA Clearance for KT501 Investigational New Drug Application |...
investigational new drugus fdakalitherapeuticsreceives
https://niuetechpost.com/article/897177350-priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in...
new drug applicationand priorityannouncesfdaacceptance
https://www.oncnursingnews.com/view/fda-accepts-new-drug-application-to-darolutamide-plus-adp-for-mhspc
FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC | Oncology Nursing News
Oct 10, 2026 - The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
new drug applicationoncology nursingfdaacceptsdarolutamide
https://www.seychelleshealthnews.com/article/871901641-biofrontera-inc-announces-filing-of-supplemental-new-drug-application-snda-for-the-treatment-of-superficial-basal-cell-carcinoma-sbcc-with
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of...
new drug applicationfor theincannouncesfiling
https://ir.unicycive.com/news/detail/116/unicycive-therapeutics-announces-resubmission-of-new-drug
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum...
Stay current with Unicycive Therapeutics press releases, business updates, and financial results announcements for UNCY investors.
new drug applicationtherapeuticsannouncesresubmissionnda
https://www.healthnewsofalabama.com/article/845665891-achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment...
new drug applicationlife sciencesachieveannouncesfda